Back to Search
JUDITH KARP, M.D.
M.D.
Medical Oncology Physician
NPI: 1336196518Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D17912(MD)
Research & Publications (20)
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
PMID 19109557·Blood·2009
3-trial
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
PMID 18483374·Clin Cancer Res·2008
3-trial
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
PMID 17640728·Leuk Res·2008
3-trial
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
PMID 17882662·Cancer Invest·2007
6-review
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
PMID 17671131·Clin Cancer Res·2007
3-trial
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
PMID 17562873·Blood·2007
3-trial
Trying to improve clinical outcome in AML: lessons from negative trials.
PMID 15863196·Leuk Res·2005
8-other
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
PMID 16556050·Future Oncol·2005
6-review
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
PMID 16322302·Clin Cancer Res·2005
3-trial
Targeting the process of farynesylation for therapy of hematologic malignancies.
PMID 16305490·Curr Mol Med·2005
6-review
Farnesyl transferase inhibition in hematologic malignancies.
PMID 16280111·J Natl Compr Canc Netw·2005
8-other
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
PMID 15173063·Clin Cancer Res·2004
3-trial
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
PMID 12538483·Clin Cancer Res·2003
8-other
Current status of clinical trials of farnesyltransferase inhibitors.
PMID 11673687·Curr Opin Oncol·2001
6-review
Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
PMID 11523024·Semin Hematol·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1336196518
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile